BioWorld Science

Aug. 31, 2012

View Archived Issues

Fifth phase III study of QVA-149 meets primary endpoint

Read More

New Afinitor formulation approved in U.S.

Read More

Creabilis products show promise as topical analgesics

Read More

PAR1 receptor antagonist prevents heart failure-induced atrial remodeling

Read More

Topical cream improves female sexual arousal disorder in phase III trial

Read More

Research at Kyowa Hakko Kirin produces new calcium channel antagonists

Read More

Merck KGaA patents novel protein kinase inhibitors

Read More

Novel inhibitors of JAK3 presented

Read More

New heat shock protein inhibitors designed in Japan

Read More

Lead product for Parkinson's disease advances through preclinical studies

Read More

Zinc peptidase implicated in ACS pathogenesis

Read More

Humira indication broadened in Europe

Read More

Enrollment complete in phase Ib trial of CALAA-01

Read More

ARIAD submits MAA to EMA

Read More

PharmaMar product gets orphan drug designation

Read More

Exelixis provides update on FDA meeting for cabozantinib

Read More

Infradure tissue implant cleared for two hepatitis C trials in Israel

Read More

Genmab and Janssen Biotech form worldwide agreement

Read More

New drug approved for IBS-C and CIC

Read More

Sunovion signs definitive acquisition agreement

Read More

FDA grants orphan drug designation to ARLN-05

Read More

Lead Nordic Nanovector product clear to enter clinic

Read More

Bayer HealthCare submits NDA for regorafenib

Read More

New genetic test predicts response to antipsychotics/antidepressants

Read More

PR-610 enters phase I/II study

Read More